A new contender in atopic dermatitis treatment

Rezpegaldesleukin, an interleukin-2 receptor agonist, is making waves in dermatology. The drug selectively expands regulatory T cells (Tregs) — immune cells that help keep inflammation in check — and showed significant improvements in skin clearance and itch reduction in adults with moderate-to-severe atopic dermatitis (AD) in the phase 2b REZOLVE-AD trial, published in The Lancet.

The randomized, double-blind, placebo-controlled trial enrolled 393 biologic-naive adults across 107 sites in 10 countries. Participants received one of three dosing regimens of rezpegaldesleukin or placebo over 16 weeks.

By the Numbers

• EASI score reductions vs. placebo (2%): 61% (24 µg/kg every 2 weeks), 58% (18 µg/kg every 2 weeks), 53% (24 µg/kg every 4 weeks)
• EASI-75 response rates: 42–46% with rezpegaldesleukin vs. 17% with placebo
• Itch NRS response rates: 35–42% with top doses vs. 16% with placebo
• Treatment-emergent adverse events: 80% of patients; only 2% were serious; no related deaths

Why it matters

This is reportedly the first large placebo-controlled trial to validate the immunomodulatory role of Tregs in a clinical setting — 25 years after their discovery. With a rapid onset of efficacy and a clean safety profile, rezpegaldesleukin could offer a meaningful new option for the millions of patients living with hard-to-treat eczema.